Current Report Filing (8-k)
May 22 2020 - 4:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 22, 2020
Eloxx Pharmaceuticals, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-31326
|
|
84-1368850
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
950 Winter Street
Waltham, MA
|
02451
|
(Address of principal executive offices)
|
(Zip Code)
|
(Registrant’s telephone number,
including area code): (781) 577-5300
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value per share
|
ELOX
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
ITEM 5.07
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
(a) The annual meeting of stockholders of Eloxx Pharmaceuticals,
Inc. (the “Company”) was held on May 20, 2020.
(b) Stockholders voted on the matters set forth below:
Proposal 1. Election of Directors:
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Zafrira Avnur, Ph.D.
|
|
20,901,103
|
|
86,487
|
|
6,223,430
|
Tomer Kariv
|
|
20,890,688
|
|
96,902
|
|
6,223,430
|
Martijn Kleijwegt
|
|
20,923,026
|
|
64,564
|
|
6,223,430
|
Silvia Noiman, Ph.D., M.B.A.
|
|
20,917,597
|
|
69,993
|
|
6,223,430
|
Ran Nussbaum
|
|
20,877,141
|
|
110,449
|
|
6,223,430
|
Steven Rubin
|
|
18,138,879
|
|
2,848,711
|
|
6,223,430
|
Jasbir Seehra, Ph.D.
|
|
20,900,883
|
|
86,707
|
|
6,223,430
|
Gadi Veinrib
|
|
20,900,573
|
|
87,017
|
|
6,223,430
|
Gregory C. Williams, Ph.D., M.B.A.
|
|
20,918,642
|
|
68,948
|
|
6,223,430
|
Proposal 2. Ratification of Appointment Deloitte & Touche
LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2020:
For
|
27,164,875
|
Against
|
23,624
|
Abstain
|
22,521
|
Broker Non-Votes
|
0
|
Proposal 3. Advisory Vote on Executive Compensation:
For
|
20,867,124
|
Against
|
113,878
|
Abstain
|
6,588
|
Broker Non-Votes
|
6,223,430
|
(c) Not applicable.
(d) Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ELOXX PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Date: May 22, 2020
|
By:
|
/s/ Neil S. Belloff
|
|
|
Neil S. Belloff
|
|
|
Chief Operating Officer, General Counsel
and Corporate Secretary
|
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Sep 2023 to Sep 2024